Oncolytic Virus GMP Manufacturing: Solving Antibody Neutralization Challenges with Next Generation Sequencing

Ensuring viral safety in oncolytic virus manufacturing can be particularly complex when neutralizing antibodies interfere with traditional biosafety assays. In this session, we will explore how GMP NGS enables accurate detection of adventitious agents and supports risk mitigation when antibodies threaten viral safety assessment. You’ll gain insight into regulatory expectations, case studies, and how integrating.

Oncolytic Virus GMP Manufacturing: Solving Antibody Neutralization Challenges with Next Generation Sequencing is an official on-demand session listing associated with BioPharma Webinars. Visit the company-owned event page for the organizer's latest agenda, access details, availability, and registration or viewing instructions. UPCOMING provides this independent listing to help professionals discover the session.